Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD

Completed · Phase 2

Conditions studied: Meibomian Gland Dysfunction, Blepharitis, Demodex Infestation

In brief

The purpose of this study is to compare the safety and efficacy of TP-03, 0.25%, an eyedrop, BID vs TID dosing regimens for the treatment of meibomian gland dysfunction in patients with Demodex lid infestation.

Key facts

Study ID
NCT05454956
Run by
Tarsus Pharmaceuticals, Inc.
People needed
39
Starts
2022-08-03
Expected to finish
2023-05-18
Last updated by the study team
2025-10-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.